BR112013011041B1 - variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica - Google Patents

variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica Download PDF

Info

Publication number
BR112013011041B1
BR112013011041B1 BR112013011041-4A BR112013011041A BR112013011041B1 BR 112013011041 B1 BR112013011041 B1 BR 112013011041B1 BR 112013011041 A BR112013011041 A BR 112013011041A BR 112013011041 B1 BR112013011041 B1 BR 112013011041B1
Authority
BR
Brazil
Prior art keywords
variant
factor viii
fviii
amino acids
seq
Prior art date
Application number
BR112013011041-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013011041A2 (pt
Inventor
Chee Kong Lai
Roddy Kevin Stafford
Original Assignee
Baxalta GmbH
Baxalta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH
Publication of BR112013011041A2 publication Critical patent/BR112013011041A2/pt
Publication of BR112013011041B1 publication Critical patent/BR112013011041B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112013011041-4A 2010-11-05 2011-11-04 variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica BR112013011041B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41043710P 2010-11-05 2010-11-05
US61/410437 2010-11-05
PCT/US2011/059297 WO2012061689A2 (en) 2010-11-05 2011-11-04 A new variant of antihemophilic factor viii having increased specific activity

Publications (2)

Publication Number Publication Date
BR112013011041A2 BR112013011041A2 (pt) 2017-06-06
BR112013011041B1 true BR112013011041B1 (pt) 2021-05-25

Family

ID=46025129

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013011041-4A BR112013011041B1 (pt) 2010-11-05 2011-11-04 variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica

Country Status (18)

Country Link
US (2) US9150637B2 (https=)
EP (1) EP2635297B1 (https=)
JP (1) JP5922141B2 (https=)
KR (1) KR101948337B1 (https=)
CN (1) CN103298483B (https=)
AU (1) AU2011323236B2 (https=)
BR (1) BR112013011041B1 (https=)
CA (1) CA2816575C (https=)
CO (1) CO6720990A2 (https=)
DK (1) DK2635297T3 (https=)
EA (1) EA035447B1 (https=)
ES (1) ES2721478T3 (https=)
IL (1) IL226158B (https=)
MX (2) MX347503B (https=)
MY (1) MY165089A (https=)
SG (2) SG10201509149VA (https=)
WO (1) WO2012061689A2 (https=)
ZA (1) ZA201303816B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123200A1 (en) 2015-01-30 2016-08-04 Emory University Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto
KR102219859B1 (ko) 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
ATE72838T1 (de) 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
JPS6281327A (ja) 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
JPS6485927A (en) 1987-09-29 1989-03-30 Green Cross Corp Hepatitis b vaccine
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
JPH0626980Y2 (ja) 1987-11-26 1994-07-20 ソニー株式会社 誤消去防止機構
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5888974A (en) 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
CA2162497A1 (en) 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α１プロテアーゼインヒビターの製造方法
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
AU6291896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
PT1754718E (pt) * 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
WO1999029848A1 (en) 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP2921180B1 (en) 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
DK1194161T3 (da) 1999-07-13 2006-02-13 Biovitrum Ab Stabile faktor VIII-sammensatninger
US6333192B1 (en) 1999-08-09 2001-12-25 North Carolina State University Method of producing an undifferentiated avian cell culture using avian primordial germ cells
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US7282562B2 (en) 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR100638184B1 (ko) 2000-09-19 2006-10-26 에모리 유니버시티 변형된 인자 ⅷ
WO2003031598A2 (en) * 2001-10-05 2003-04-17 Emory University Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
AU2002364509A1 (en) 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
SI1750733T1 (sl) 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
AU2007338298B2 (en) * 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
WO2009075772A1 (en) * 2007-12-06 2009-06-18 Wyeth Crystal structure of human factor viii and uses thereof

Also Published As

Publication number Publication date
CN103298483A (zh) 2013-09-11
US20130296244A1 (en) 2013-11-07
IL226158A0 (en) 2013-06-27
BR112013011041A2 (pt) 2017-06-06
KR20140114266A (ko) 2014-09-26
EA201390654A1 (ru) 2014-01-30
EP2635297A4 (en) 2014-06-25
SG10201509149VA (en) 2015-12-30
EP2635297A2 (en) 2013-09-11
AU2011323236A1 (en) 2013-06-06
US20150353625A1 (en) 2015-12-10
JP2013545459A (ja) 2013-12-26
EP2635297B1 (en) 2019-02-27
ZA201303816B (en) 2021-05-26
CN103298483B (zh) 2017-04-12
DK2635297T3 (da) 2019-05-06
MY165089A (en) 2018-02-28
CO6720990A2 (es) 2013-07-31
MX351220B (es) 2017-10-05
IL226158B (en) 2019-08-29
CA2816575C (en) 2019-06-11
ES2721478T3 (es) 2019-07-31
US10053500B2 (en) 2018-08-21
MX2013005047A (es) 2013-12-06
MX347503B (es) 2017-04-26
WO2012061689A2 (en) 2012-05-10
AU2011323236B2 (en) 2017-03-30
KR101948337B1 (ko) 2019-02-14
JP5922141B2 (ja) 2016-05-24
US9150637B2 (en) 2015-10-06
CA2816575A1 (en) 2012-05-10
SG190136A1 (en) 2013-07-31
EA035447B1 (ru) 2020-06-17
AU2011323236A8 (en) 2013-07-25
WO2012061689A3 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
JP3701028B2 (ja) 高純度フォンビルブラント因子の入手方法
AU682147B2 (en) Hybrid human/porcine factor VIII
US7928199B2 (en) Stabilized proteins with engineered disulfide bonds
PT749444E (pt) Factor viii hibrido humano/animal
AU2002310438A1 (en) Stabilized proteins with engineered disulfide bonds
LOLLAR The association of factor VIII with von Willebrand factor
US20040249134A1 (en) Factor viii c2 domain variants
US10053500B2 (en) Variant of antihemophilic factor VIII having increased specific activity
ES2420535T3 (es) Nuevo proceso para la purificación altamente selectiva de dos proteínas plasmáticas: factor de von willebrand (vwf) y fibronectina (fn).
Liles et al. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B
HK1189486B (en) A new variant of antihemophilic factor viii having increased specific activity
HK1189486A (en) A new variant of antihemophilic factor viii having increased specific activity
Paik et al. Comparability studies of new 3rd generation recombinant human factor VIII GreenGene F after improvement of formulation and viral inactivation/removal process
TW202317178A (zh) 因子ⅷ嵌合蛋白的配製品及其用途
BR112019003302B1 (pt) Proteína de fusão fator viii de coagulação de sangue humano altamente glicosilada, molécula de dna, vetor, composição farmacêutica, e método de preparação e seu uso
White et al. Clinical Trials of Recombinant Factor VIII

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAXALTA GMBH (CH) , BAXALTA INCORPORATED (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/11/2011, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: BAXALTA INCORPORATED (US) ; BAXALTA GMBH (CH)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2652 DE 03/11/2021 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)